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FKBP Ligands—Where We Are and
Where to Go?
Jürgen M. Kolos, Andreas M. Voll, Michael Bauder and Felix Hausch*
Department of Chemistry, Institute of Chemistry and Biochemistry, Darmstadt University of Technology, Darmstadt, Germany
In recent years, many members of the FK506-binding protein (FKBP) family were
increasingly linked to various diseases. The binding domain of FKBPs differs only in
a few amino acid residues, but their biological roles are versatile. High-affinity ligands
with selectivity between close homologs are scarce. This review will give an overview of
the most prominent ligands developed for FKBPs and highlight a perspective for future
developments. More precisely, human FKBPs and correlated diseases will be discussed
as well as microbial FKBPs in the context of anti-bacterial and anti-fungal therapeutics.
The last section gives insights into high-affinity ligands as chemical tools and dimerizers.
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INTRODUCTION
FK506-binding proteins (FKBPs) belong to the immunophilin family. Like other immunophilins
many FKBPs possess a cis-trans peptidyl-prolyl isomerase (PPIase) activity. In addition, they can
act as a co-receptor for the natural products FK506 and Rapamycin. By binding these drugs, a
complex is formed, which exhibits immunosuppressive effects via a gain-of-function mechanism.
Furthermore, the endogenous functions of FKBPs are increasingly being uncovered and several
homologs have been linked to pathological processes.
FKBPs are present in all eukaryotes, ranging from yeasts to humans, and expressed in most
tissues. Mammalian FKBPs can be subdivided into four groups: the cytoplasmic, endoplasmic
reticulum, nuclear, and TPR (tetratricopeptide repeats)-containing FKBPs. FKBP51, a member of
the TPR-containing group, is depicted in Figure 1A. The FK506-binding domain (FK1) is shown
in red. The tertiary structure of this domain is highly similar in most FKBPs which are therefore
not easily distinguishable (Figure 1B). The crucial task for drug development is the exploitation of
small variations in the biding pocket to achieve selectivity between different FKBPs.
This review will focus on the FK506-binding pocket of FKBPs and their ligands, including
the prototypic natural products, synthetic analogs, endogenous ligands, and protein partners.
Moreover, FKBP ligands will be discussed in the context of anti-microbials and as chemical tools.
FKBP12 AND FKBP12.6
FKBP12 was first described in 1989 by Harding et al. (1989) and Siekierka et al. (1989). With a
molecular weight of 12 kDa, it is the smallest member of the FKBP family. It contains the PPIase
core domain, which is found in many FKBPs. It occurs in most species and tissues and is essential
for mammalian life. Knock-out of FKBP12 in mice produced an embryonic lethal phenotype due
to severe heart defects attributed to interference with the ryanodine receptor (Shou et al., 1998).
Furthermore, FKBP12 is linked to various diseases including Alzheimer’s and Parkinson’s disease,
but its distinct role still needs to be elucidated.
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FIGURE 1 | Structures of FKBPs and their interaction partners. (A) Structure
of FKBP51 (pdb-ID: 1KT0). The FK1 domain is depicted in red, the FK2
domain in green, TPR domains in blue. The pale-yellow region corresponds to
a putative calmodulin binding domain. (B) Superposition of the FK506-binding
domains of FKBP12 (1FKJ, green), FKBP13 (4NNR, gray), FKBP25 (5D75,
blue), FKB51 (3O5R, yellow), and FKBP52 (4LAX, salmon). The conserved
active site residues are highlighted as sticks, the bound FK506 is omitted for
clarity. (C) Inhibitory complex (1TC0) of FKBP12 (green), FK506 (pink sticks),
and calcineurin (cyan and blue).
The first ligands described for FKBP12 are the natural
products Rapamycin and FK506. Both compounds are potent
immunosuppressants in complex with FKBPs (best described
for FKBP12) and act via a gain-of-function mechanism.
The FKBP12-FK506 complex (depicted in Figure 1C) binds
calcineurin (Griffith et al., 1995), a key enzyme in T-cell
activation (Rosen and Schreiber, 1992; Kissinger et al., 1995),
while the FKBP12-Rapamycin complex binds to the FKBP
Rapamycin binding (FRB) domain of the mammalian target
of Rapamycin (mTOR) (Liang et al., 1999; Banaszynski et al.,
2005), a kinase involved in cell growth and cell proliferation
(Waickman and Powell, 2012). Inhibition of both pathways
leads to an immunosuppressive response. Therefore, FK506
and Rapamycin are used as drugs to stop allograft rejection
in post-transplantation patients (Demetris et al., 1990; Fung
et al., 1990; Todo et al., 1990; Armitage et al., 1991; Shapiro
et al., 1991; Saunders et al., 2001; Zhang et al., 2018).
Rapamycin is especially used in renal transplantation, where it
displays less toxicity compared to related immunosuppressive
agents (e.g., FK506) (Andoh et al., 1996) and in heart
transplantations (Asleh et al., 2018). However, Rapamycin
is often co-administered with cyclosporin A (CsA), since
it was proven more active in combination with CsA or
inactive on its own in some cases (Sharkey and Butcher,
1994; Patel et al., 2011). Although the immunosuppressive
activity of FK506 is depending on the FK506-FKBP12 complex
and calcineurin inhibition (Gold, 1997; Snyder et al., 1998),
the neurotrophic activity is not. FK506 and other non-
FKBP12-binding immunophilins displayed neuroprotective and
neuroregenerative effects regardless of FKBP12-binding or
FKBP12 presence at all (Winter et al., 2000; Costantini et al.,
2001; Guo et al., 2001; Tanaka et al., 2002; Gold et al., 2005).
Recently, it was shown that the neuritotrophic effects of FKBP
ligands could be in part attributed to inhibition of FKBP51 (Gaali
et al., 2015). Whether inhibition of FKBP12 can have beneficial
neuronal effects is still unclear (Hausch, 2015). Therefore, high-
quality FKBP12 ligands lacking immunosuppressive properties
and off-target binding would be highly desirable.
Nature-Inspired Ligands
Crystal structures revealed that Rapamycin and FK506 bind
to the pocket of FKBP12 via the pipecolate moiety, while the
remaining part of the molecule points outwards and enables
ternary complexes [Van Duyne et al., 1991a,b, 1993]. Early
development of FKBP12 ligands focused on the improvement
of these natural compounds by simplifying the structure and
removing the loop which leads to immunosuppression. Various
research groups developed synthetic cyclic and acyclic FK506
analogs by retaining the seemingly important pipecolinyl α-
ketoamide function and modifying the outside loop (Figure 2)
(Birkenshaw et al., 1994; Armistead et al., 1995; Luengo et al.,
1995). The most potent inhibitor (2 nM) of this series had a t-
pentyl residue on the diketo moiety and a diarylpropyl moiety
on the ester. Notably, the stereochemistry highly affected the
potency, since the R-isomer was ∼40 times more active than the
S-isomer (Holt et al., 1994).
Further variation of the side chains resulted in synthetic
ligands, which were reported to bind with similar affinities
to FKBP12 as FK506. Examples are GPI-1485 and the
corresponding prodrug, GPI-1046 (Guilford Pharmaceuticals
and Amgen) (Steiner et al., 1997), V10367 (Vertex
Pharmaceuticals) (Armistead et al., 1995), and ElteN378
(Martina et al., 2013). GPI-1046 and GPI-1485 were discussed
as a potential treatment option for Alzheimer’s and Parkinson’s
disease (Steiner et al., 1997; Sauer et al., 1999; Ross et al., 2001;
Marshall and Grosset, 2004; Caporello et al., 2006; NINDS NET-
PD Investigators, 2007). However, numerous other research
groups subsequently observed no or only negligible binding of
GPI-1046 to FKBP12 (Harper et al., 1999; Winter et al., 2000;
Bocquet et al., 2001; Eberling et al., 2002). GPI-1046 or GPI-1485
should not be regarded or used as FKBP ligands. Several research
groups reported V10367 as a promising drug for neuroprotection
and nerve regeneration (Costantini et al., 1998; Kupina et al.,
2002; Klettner and Herdegen, 2003; Rosenstiel et al., 2003),
but it is not known if the effect is derived from FKBP binding.
ElteN378 was developed by Martina et al. and reported to have
a Ki value of 3 nM determined by a fluorescent quenching assay
(Martina et al., 2013).
Polycyclic Ligands
By using computational modeling, Babine et al. discovered
that bridged bicyclic structures fit well to the FKBP12 binding
site. This was further confirmed with crystal structures (Babine
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FIGURE 2 | The natural drugs FK506 and Rapamycin and synthetic derivatives.
FIGURE 3 | Bicyclic and polycyclic ligands for FKBPs.
et al., 1995) and led to the synthesis of many bicyclic
scaffolds (Figure 3) including [7.3.1] and [8.3.1] macrocycles
(Babine et al., 1996), bicyclic diamides (Dubowchik and
Provencal, 2004), bicyclic aza-amides (Wang and Hausch, 2016),
and chiral bicyclic proline analogs (Limburg et al., 2003).
Katoh et al. developed polycyclic azaamides as inhibitors of
isomerization activity (Katoh et al., 2003). Two compounds,
AG5473 and AG5507, displayed high binding affinity for
FKBP12, with 84 nM and 54 nm, respectively (Guo et al.,
2000). Further derivatization of this scaffold by interconverting
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FIGURE 4 | Cocrystal structure of a diazobicyclo [4.3.1]decan-2-one with the
FK1 domain of FKBP51 (representative for FKBPs). The protein surface is
depicted in gray; the key amino acids are highlighted as yellow sticks, while
the ligand is green. Blue atoms correspond to nitrogen, red atoms to oxygen.
Hydrogen bonds are shown in yellow, van der Waals interactions in magenta.
The side chain of Lys121 has been omitted for clarity.
the α-keto-amide to sulfonamides, sulfamides, ureas and α,α-
difluoro amides resulted in no or only marginal improvements
in affinity (Hudack et al., 2006).
Following the idea of rigidification and bridging the
pipecolate core, Hausch et al. developed a new class of 3,10-
diazabicyclo[4.3.1]-decan-2-one sulfonamides. This very rigid
structure closely mimics the active conformation of FK506,
indicated by the dihedral O=C2-C1-N3 angle, which strongly
resembles the FKBP-bound conformation of unconstrained
FKBP ligands (both∼175◦). Crystal structures elucidated the key
interactions, some of which are the C1-O1 Ile87-N hydrogen bond
(FKBP51 numbering), a bifurcated hydrogen bond of Tyr113 to
one of the S=O oxygens as well as to N10 and van der Waals
contacts of the installed linker with Phe77 (Figure 4) (Wang et al.,
2013). Further improvements were achieved by modifications
of the C5 position, resulting in highly ligand-efficient FKBP
inhibitors with neurotrophic and anti-microbial activity (Bischoff
et al., 2014; Pomplun et al., 2015, 2018). Although these ligands
displayed high affinities toward FKBP12, it is noteworthy that
several other FKBPs were also bound with nanomolar affinity
and without selectivity between FKBP12 and its close homolog
FKBP12.6.
Biochemical Mechanisms of FKBP12 and
FKBP12.6
The first described biochemical function of FKBP12 was the
PPIase activity that is conserved in many, but not all FKBP
homologs. So far, it has not been possible to unambiguously
show how this catalytic activity affects cellular processes. Two
signaling pathways are well established to be modulated by
FKBP12, ryanodine receptors (RyRs) and transforming growth
factor β (TGFβ)/activin-like receptors. However, both types of
receptors are clearly regulated by FKBP12 through protein-
protein interactions that utilize the PPIase active site but to the
best of our knowledge do not involve a cis-trans isomerization
step.
FKBP12 was repeatedly shown to bind to type I receptors
of the TGFβ family. Specifically, it binds to the glycine- and
serine-rich sequence (GS domain) of TGFβRI (Huse et al.,
1999) or activin receptor-like kinase-2 (ALK2) (Chaikuad et al.,
2012), stabilizing these kinases in an inactive conformation and
blocking access of substrates. This is thought to prevent leaky
signaling of the receptor kinases. Mutations in the GS region
of ALK2 that abolish FKBP12 binding are associated with the
connective tissue disease fibrodysplasia ossificans progressiva
(FOP), but with milder symptoms compared to other ALK
mutations (Machiya et al., 2018). FKBP12.6, the closest analog
to FKBP12, with 85% amino acid identity and a highly similar
tertiary structure (Snyder and Sabatini, 1995; Marks, 1996, 2002)
is also able to bind to ALK2 (pdb-ID: 4C02) but its role, as well
as those of other FKBP homologs, on TGFβ/activin signaling is
unknown.
FKBP12 and FKBP12.6 are well documented components of
RyR complexes, which intracellularly amplify Ca2+-signaling in
myocytes to evoke muscle contraction. Recent cryogenic electron
microscopy (Cryo-EM) structures have elucidated the FKBP
binding site in the ryanodine receptor complex, where FKBP12
and FKBP12.6 occupied identical positions bridging the SPRY1
(a sequence repeat discovered in the splA kinase and ryanodine
receptors) and the handle domains (Yan et al., 2014; des Georges
et al., 2016). However, higher resolution structures are needed
to elucidate the details of the FKBP-RyR binding interface and
differences between FKBP12/12.6 and RyR1 and RyR2.
While the RyR1-FKBP12 complex is present in skeletal
muscle, the homologous RyR2 and FKBP12.6 seem to have
evolved as a specialized system to control cardiac muscle
stimulation in mammals. Numerous studies have investigated
the role of FKBP12.6 in heart biology, however, with highly
controversial findings. Some reports suggest that FKBP12 is
stronger associated with RyR1 while FKBP12.6 is stronger
connected to RyR2 function (Li et al., 2012; Venturi et al.,
2014). Others observed that there is no selectivity for RyR1
but specificity of cardiac RyR2 for FKBP12.6 over FKBP12
(Timerman et al., 1996) or at least higher affinity in heart cells
toward FKBP12.6 (Guo et al., 2010; Oda et al., 2015). Fleischer
et al. systematically investigated 18 amino acids, which differ
between these two proteins. They identified three amino acids
(Gln31, Asn32, and Phe59) which are responsible for selective
binding of FKBP12.6 to RyR2. By site-directed mutagenesis they
made triple mutants of FKBP12 and FKBP12.6 with the amino
acids of the other isoform. The triple mutant of FKBP12 showed
RyR2 selectivity, while the triple mutant of FKBP12.6 had no
selectivity for RyR2. Control experiments displayed that both
isoforms still bind to RyR1 (Xin et al., 1999). In an attempt
to reconcile discrepancies regarding the role of FKBP12.6,
Zhao et al. measured the stimulation of ryanodine receptors
(primarily RyR2) by voltage-gated Ca2+ channels (primarily
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CaV1.2) in mouse cardiomyocytes (Zhao et al., 2017). They
observed enhanced Ca2+ spark frequency and quicker voltage-
gated Ca2+ channel-RyR2 coupling in FKBP12.6-deficient and
FK506- or Rapamycin-treated cardiomyocytes.
Recently, FKBP12.6 was found to protect the heart from
hypertrophy through inhibition of Ca2+/calmodulin mediated
signaling pathways (Xiao et al., 2018). A pending question is
how these observations translate to temporal RyR2-FKBP12.6
disruption in intact animals as well as to humans.
FKBP13 AND OTHER ENDOPLASMIC
FKBPS
The second characterized member of the FKBP family, FKBP13,
shares 43% amino acid sequence identity with FKBP12 and
has a conserved PPIase domain, which binds to FK506 and
Rapamycin (Jin et al., 1991). In contrast to FKBP12, FKBP13
is a membrane-associated protein localized to the lumen of the
endoplasmic reticulum (ER). It contains a C-terminal Arg-Thr-
Glu-Leu (RTEL) sequence responsible for ER retention (Nigam
et al., 1993; Bush et al., 1994). Further, FKBP13 is thought to
play a role in protein folding in the ER (Walensky et al., 1998).
Recently, FKBP13 was identified as a key regulator of protein
homeostasis in long-lived plasma cells (Jeong et al., 2017). By
interaction with immunoglobulin (Ig) the ubiquitination of Ig
is facilitated, leading to lowered levels of ER stress. FKBP13
knockdown in cells increased the amount of secreted IgA, while
overexpression resulted in decreased secretion of IgA. The latter
effect was inhibited by treating cells with Rapamycin, possibly
by blocking the binding site responsible for correct folding
of IgA. Ishikawa et al. investigated the role of endoplasmic
FKBPs as chaperones for collagen biosynthesis. Since collagen
contains multiple proline residues, the cis-trans isomerization
of the amino acid is thought to be the rate-determining step
during triple-helix formation. Post-translational modifications
of proline to hydroxyproline provide thermal stability, and
therefore, theymodulate the folding of the triple helix of collagen.
FKBPs bind differently to these substrates. FKBP13 has a low
affinity toward hydroxylated substrates, while FKBP19, FKBP22,
and FKBP65 were found to prefer hydroxylated substrates
(Ishikawa et al., 2017). However, since FKBP65 has four FKBP-
like domains, which are poorly characterized regarding the
binding of ligands, it is difficult to pin down the observed effects
to one of these domains. FKBP65 is further associated with lysyl
hydroxylase 2 (LH2), a key regulator of collagen cross-linking
stability. The FKBP65-LH2-complex promotes dimerization of
LH2 and thereby positively modulates its activity (Gjaltema et al.,
2016; Chen et al., 2017). While FKBP65 knockout completely
inhibits its PPIase activity and consequently LH2mediated cross-
linking, FK506 evokes only partial inhibition (∼25%) (Zeng et al.,
1998). More potent inhibitors could be used in LH2 associated
pathologies, like fibrosis (van der Slot et al., 2005; Remst et al.,
2013) and cancer metastasis (Eisinger-Mathason et al., 2013;
Gilkes et al., 2013; Chen et al., 2015).
Although FKBP13 is mostly known for its function in
the ER, it was also found in erythrocytes which lack ER.
Walensky et al. reported the association of FKBP13 with the
homolog 4.1G of the red blood cell protein 4.1 (4.1R) and
suggested a function of FKBP13 in the membrane cytoskeleton
of mammalian cells (Walensky et al., 1998). In the context of
Alzheimer’s disease, inhibition of FKBP13 (for instance by FK506
or Rapamycin) was found to destabilize presenilins, a family of
transmembrane proteins, which are responsible for γ-secretase
activity (Boulianne, 2006). Inhibition of the γ-secretase complex
results in decreased formation of amyloid-β proteins, which are
believed to play a key part in the development of Alzheimer’s
disease (Hamley, 2012).
FKBP25
FKBP25 was originally purified from bovine tissue (Galat
et al., 1992). It shows 97% homology with the human FKBP25
(hFKBP25) (Hung and Schreiber, 1992). The human FKBP25
is a nuclear protein which consists of two domains linked by
a long random coiled loop (Prakash et al., 2015). While the C-
terminal domain is a PPIase domain found in many FKBPs, the
N-terminal basic tilted helix bundle (BTHB) domain is unique
within the FKBP family (Helander et al., 2014). FKBP25 has
been shown to interact with the histone deacetylases HDAC1 and
HDAC2 as well as with their transcriptional regulator Yin Yang 1
(YY1) (Yang et al., 2001). Further, it interacts with DNA via both
domains (Prakash et al., 2016b), with RNA (Dilworth et al., 2017)
and withmouse double minute 2 (MDM2) (Ochocka et al., 2009).
Recently, FKBP25 was identified to play a role in the proliferation
of non-small cell type lung cancer cells (NSCLC) by modulating
Sp1/HDAC2/p27 (Zhu et al., 2017). Furthermore, FKBP25 was
found to be amicrotubule-associated protein (MAP) that shuttles
between nucleus and cytoplasm and stabilizes the microtubule
network by direct binding of the C-terminal domain (Dilworth
et al., 2018).
FKBP Domain
The C-terminal domain binds immunophilin ligands like
Rapamycin and FK506, although compared to other FKBPs the
affinity for FK506 is substantially lower (Rapamycin Ki 0.9 nM,
FK506 200 nM) (Jin et al., 1992; Liang et al., 1996; Prakash
et al., 2016a). Most of the interactions are comparable, with
the exception of Lys170, which forms 2 hydrogen bonds to
Rapamycin. These bonds are not present in the crystal structure
with FK506. Additionally, the interaction with Gly169 is lost,
suggesting a lack of donor atoms responsible for the reduced
affinity of FK506 (Prakash et al., 2016a). The crystal structures
give an insight in the different binding to hFKBP25, but further
experiments are necessary to evaluate the role of Lys170.
BTHB Domain
Although no ligands were developed for the C-terminal
domain of FKBP25, many research groups focused on the
better understanding of the N-terminal part. This helix bundle
domain was found to mediate protein-protein interaction for
ubiquitination and therefore degradation of oncogene mouse
double minute 2 (MDM2), which leads to an enhanced
expression of tumor suppressor protein p53 (Ochocka et al.,
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2009). Recently, interaction with double-stranded RNA (dsRNA)
(Dilworth et al., 2017) and a role in ischemia stress injury
protection (Jiang et al., 2018) were disclosed.
Full Length FKBP25
Prakash et al. determined the NMR solution structure of full-
length human FKBP25 in order to investigate the DNA-binding
mechanism of FKBP25. The C- and N-terminal domains of
FKBP25 interact with each other; especially the α2 and α4 helices
of the helix bundle domain and the basic loop of the FKBP
domain play a role in binding to DNA. Furthermore, the basic
loop was found to be larger compared to other FKBPs and rich in
lysine residues, probably favoring DNA binding (Prakash et al.,
2016b).
AIPL1
The aryl hydrocarbon receptor-interacting protein-like 1
(AIPL1) belongs to the FKBP family because it harbors an
FKBP-like domain. Interestingly, this domain is devoid of PPIase
activity (Yadav and Artemyev, 2017). Mutations in the AIPL1-
encoding gene were identified as one of the factors causing
Leber congenital amaurosis (LCA), an autosomal recessive
inherited retinopathy leading to blindness in early childhood.
Compelling evidence has shown that AIPL1 functions as an
obligatory chaperone for phosphodiesterase 6 (PDE6), a key
protein that converts stimuli from photoactivated G proteins to
electrical signals in retinal neurons (Gopalakrishna et al., 2016;
Sacristan-Reviriego et al., 2017).
Importantly, the FKBP-like domain of AIPL1 was shown
to bind farnesyl and geranyl moieties, which are essential
posttranslational modifications of PDE6. Recently, the structural
details of isoprenyl binding by the AIPL1-FKBP domain were
elucidated (Yadav et al., 2017). X-ray and NMR-studies revealed
that the core and loop-region of AIPL1-FKBP rearranges to open
a hydrophobic cavity capable of farnesyl/geranylgeranyl binding.
FKBP51 AND FKBP52
FKBP51
The FK506-binding protein 51 (FKBP51), encoded by the FKBP5
gene, acts as a cochaperone for the heat shock protein 90 (Hsp90)
(Riggs et al., 2003) and is best known for the negative regulation
of glucocorticoid and progesterone receptors (Pratt and Toft,
1997; Cioffi et al., 2011; Schmidt et al., 2012; Dunyak and
Gestwicki, 2016).
FKBP51 structurally consists of a N-terminal FK1 domain,
which displays PPIase activity, a PPIase-like FK2 domain
and a C-terminal TPR domain. The FK1 domain binds the
immunosuppressive drugs Rapamycin and FK506 with slightly
reduced affinities compared to FKBP12 (Rapamycin: K i = 3.7
± 0.9 nM, FK506: K i = 104 ± 14 nM) (Kozany et al., 2009). It
shares 51% amino acid identity with FKBP12 (Blackburn and
Walkinshaw, 2011). The FK2 domain adopts a typical FKBP-like
structure, but it neither shows measurable isomerase activity in
vitro, nor does it bind FK506 or Rapamycin (Storer et al., 2011;
Dunyak and Gestwicki, 2016). Interestingly, the FKBP51-FK2
domain has greater similarity to FKBP38 than its respective FK1
domain (Blackburn and Walkinshaw, 2011). The TPR domain
forms the docking site for Hsp90 (Young et al., 1998; Assimon
et al., 2015).
A study on the interaction of FKBP51 with the protein kinase
B (Akt) showed that binding of FKBP51 to Akt is independent
from FK506 binding pocket. Several inhibitors of the FKBP51-
FK1 domain like FK506, FK1706 or Rapamycin were tested for
their effect on Akt binding, but none of them displayed any
mentionable results (Fabian et al., 2013).
Independent reports on the role of FKBP51 in the
pathogenesis of psychiatric disorders and stress-related diseases
reveal it to be an attractive drug target (Schmidt et al., 2012). In
numerous studies FKBP51-deficient mice showed an improved
stress resistance and an improved stress-coping behavior
(O’Leary et al., 2011; Touma et al., 2011; Hartmann et al., 2012;
Albu et al., 2014; Hoeijmakers et al., 2014; Sabbagh et al., 2014).
A follow up study on stress resiliency in aged mice displayed
a learning enhancement caused by the absence of FKBP51
(Sabbagh et al., 2014). In humans, genetic variations of the
FKBP51-encoding gene FKBP5 that were shown to enhance
expression of FKBP51 (Klengel et al., 2013) are associated with
various stress-related disorders, especially in an environmental
background of early life trauma (Klengel et al., 2013; Zannas
and Binder, 2014; Zannas et al., 2016). Promising studies on
the involvement of FKBP51 in energy metabolism revealed
an enhanced expression of FKBP51 in adipocytes and adipose
tissue (Pereira et al., 2014; Sidibeh et al., 2018). Furthermore,
FKBP51-knockout mice displayed a resistance to weight gain
under both regular and high-fat diets and an improved glucose
tolerance (Stechschulte et al., 2016; Balsevich et al., 2017).
Recently, FKBP51-knockout mice showed lower hypersensitivity
in different pain models, without affecting the detection of acute
painful stimuli, which is an important protective mechanism
(Maiarù et al., 2016, 2018). Notably, Maiaru et al. were also able
to demonstrate that the pain regulatory role of FKBP51 can be
dissociated from its regulation of mood.
Inspired by the well-established role of FKBP51 as a
suppressor of the glucocorticoid receptor as well as its
involvement in the nuclear factor “kappa-light-chain-enhancer”
of activated B-cells (NF-κB) pathway, a research group from
Boehringer Ingelheim recently explored the role of FKBP51 in
models of glucocorticoid-resistant asthma (Kastle et al., 2018).
Mice overexpressing FKBP51 in airway epithelial cells were
resistant to low dose of glucocorticoids. Knockdown of FKBP51
also led to a 10-fold enhanced glucocorticoid sensitivity in
A549 cells, suggesting FKBP51 as a target for glucocorticoid-
resistant asthma. The mechanisms of FKBP51 interaction with
the glucocorticoid receptor or NF-κB are still unclear. A pending
question is, if FKBP51 inhibitors can evoke the same effect.
FKBP52
FKBP52 is the closest homolog to FKBP51, sharing 70% sequence
identity and an almost identical tertiary structure. It is encoded
by the FKBP4 gene and, like FKBP51, contains a N-terminal
FK1 domain exhibiting PPIase activity, a FKBP-like domain
(FK2) without isomerase activity and a tetratricopeptide repeat
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domain (TPR domain) located at the C-terminus (Young et al.,
1998; Cheung-Flynn et al., 2005; Storer et al., 2011). The FK1
domain shares 53% amino acid identity with FKBP12 and also
binds to Rapamycin and FK506 (Rapamycin: K i = 4.2± 0.7 nM,
FK506: K i = 23 ± 3 nM) (Kozany et al., 2009; Blackburn
and Walkinshaw, 2011). Antagonistic to FKBP51, FKBP52 acts
as positive regulator of the glucocorticoid and progesterone
receptors (PR) (Schülke et al., 2010; Gaali et al., 2015). One
possible explanation for this antagonistic behavior may be the
flexibility of a hinge, more exactly a short linker between the
FK1 and the FK2 domain of FKBP52, and its modulation by
phosphorylation (Bracher et al., 2013).
Mice lacking FKBP52 displayed female infertility and several
defects in male sexual development, which is in line with the
role of FKBP52 in hormone signaling, especially as an PR and
androgen receptor (AR) regulator (Cheung-Flynn et al., 2005;
Sivils et al., 2011; Guy et al., 2016). This hormone receptor
activity makes FKBP52 an interesting target in hormone-driven
tumors like prostate cancer, colorectal adenocarcinomas, breast
cancer, and myelomas (Storer et al., 2011; Storer Samaniego
et al., 2015). Recently, Joshi et al. were able to prove an
interaction between FKBP52 and inhibitor of differentiation 4
(ID4) in castration-resistant prostate cancer (CRPR) in vitro
(Joshi et al., 2017). In this type of cancer, prostate cancer cells
adapt to the androgen-depleted environment of the prostate. ID4
is a dominant-negative helix-loop-helix protein that promotes
de novo steroidogenesis and castration-resistance with a gene
expression signature similar to constitutive AR activity in
castrated mice. Their findings show, that ID4 regulates the AR
activity by interaction with FKBP52, whereas in absence of
ID4 FKBP52 potentiates AR signaling and leads to increased
proliferation and tumor growth. Hence, selective inhibition of
FKBP52 would be a valuable tool to further understand the
molecular alterations underlying castration resistance in prostate
cancers.
The development of inhibitors for FKBP52 was initially
strongly connected to that of FKBP51, since the FK506-binding
pockets are highly conserved and show similar binding to almost
all synthetically designed ligands except those of the SAFit
(Selective Antagonist of FKBP51) class (Feng et al., 2015a). An
early ligand for FKBP52 was an analog of SLF (Synthetic Ligand
for FKBP, Figure 5), a ligand originally developed for FKBP12.
The α-ketoamide is substituted by an aryl sulfonamide, bearing
a chlorine in both meta-positions and a hydroxy substituent
in para-position (K i = 0.71 ± 0.1µM) (Gopalakrishnan et al.,
2012b). However, this ligand shows only marginal selectivity
against FKBP51 or FKBP12.
To achieve selectivity for FKBP52 against FKBP51 and other
FKBP’s (especially FKBP12), it might be helpful to pick up on
structure-based drug design at a point before selectivity for
FKBP51 was obtained. Valuable data for the binding of FKBP52
to different ligands, as well as detailed analyses on the subtle
differences in the binding domains of FKBP51 and FKBP52, are
already existing (Bracher et al., 2013; Shi et al., 2018). In 2013
Bracher et al. suggested to exploit differences in the electrostatic
potential of residue 85. In FKBP51 this residue is a Gln, while in
FKBP52 it is a Glu. This offers the possibility to design suitable
ligands for favored interactions with FKBP52 (Bracher et al.,
2013).
Searching for FKBP52 modulators, the Cox group identified
a molecule called MJC13, that specifically inhibits the FKBP52-
enhanced AR activity in yeast and mammalian cells (De Leon
et al., 2011). This compound was suggested to act by targeting
the regulation of AR by FKBP52 through binding a regulatory
surface on the AR and preventing the FKBP52-receptor complex
from dissociation, not by selective binding to FKBP52 (Cox and
Richer, 2017). The exact mechanism and binding mode of MJC is
still unclear.
Ligand Development
As for FKBP12, the natural products FK506 and Rapamycin
were the first known potent inhibitors of FKBP51. FK506 was
used to study the pharmacological role of FKBP51 in defined
cellular models. Independent reports displayed a connection of
FKBP51 to GR binding and the effects upon treatment with
FK506 (Reynolds et al., 1999; Davies et al., 2005; Westberry et al.,
2006). In 2013, März et al. showed that complexes of Rapamycin
with larger FKBP homologs like FKBP51 can tightly bind to
mTOR, thus forming ternary complexes that allosterically inhibit
the kinase activity of mTOR. This effect was mainly discussed and
interpreted in context of a ternary complex of Rapamycin and
mTOR with FKBP12 (März et al., 2013). However, the primary
effects of FK506 and Rapamycin are the inhibition of calcineurin
(for FK506) and mTOR (for Rapamycin), which limits their use
as a probe for FKBP51 in living organisms. The search for non-
immunosuppressive immunophilin ligands for FKBP51 faces a
selectivity issue between the homologs FKBP51 and FKBP52,
since the FK506-binding sites in both proteins are completely
conserved (Blackburn and Walkinshaw, 2011). Nevertheless,
selectivity is crucial, due to the opposite effects on glucocorticoid
signaling in cells and partially also in vivo (Feng et al., 2015a).
The first synthetic ligand for FKBP51 was compound SLF
(Figure 5) with an affinity of 3.1µM for FKBP51 (Holt et al.,
1993; Keenan et al., 1998; Kozany et al., 2009). The process
of ligand development was accelerated by structural biology
and by the development of a medium-throughput assay for the
FKBP ligands. In 2009, Kozany et al. used FL-SLF, a fluorescein
derivative of SLF, for competitive fluorescence polarization assays
for most FK506 binding-competent FKBPs (FKBP12, 12.6, 13, 51,
and 52) (Kozany et al., 2009). Subsequently, this assay was used in
a high throughput screening of more than 380,000 compounds,
aiming to reveal binders to the FK506-binding pocket of FKBP51
(unpublished). However, no chemically tractable starting point
other than FK506 or Rapamycin could be identified.
An efficient co-crystallization protocol yielding high-
resolution structures of the FKBP51-FK1 domain has been
established to support the development of inhibitors (Bracher
et al., 2011). The crystal structures of FK506 and SLF in complex
with the FK1 domain of FKBP51 served as chemical starting
point for the structure-based rational design of potent and
selective FKBP51 inhibitors.
In 2012, Gopalakrishnan et al. performed the first detailed
structure-activity relationship analysis of small synthetic
molecules for the human FKBPs 51 and 52 by systematically
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FIGURE 5 | Development of early FKBP51 ligands.
exploring the contributions of substituents on affinity
(Gopalakrishnan et al., 2012a,b). Here, the pipecolic core
turned out to be essential for the binding affinity. The tert-pentyl
group in SLF was substituted by various hydroxyl-cyclohexyl
moieties, supposed to mimic the pyranose in FK506 and
Rapamycin. Unfortunately, these changes did not substantially
increase the binding affinities of the inhibitors (Gopalakrishnan
et al., 2012a). In another SAR study, the top group part of the
molecule (see Figure 5) and the pipecolic core were retained,
whereas the α-ketoamide was bioisosterically replaced by an
aryl sulfonamide (Gopalakrishnan et al., 2012b). With a solid
phase synthetic strategy, a small focused library was prepared,
resulting in ligands with submicromolar affinities for FKBP51
and FKBP52. In addition, the top group was changed to a
morpholine moiety, leading to ligand 1 (Figure 5) with 15 to
20-fold enhancement in affinity for both FKBPs compared to
SLF (IC50 (FKBP51) = 456 nM, IC50 (FKBP52) = 710 nM, IC50
(FKBP12)= 115 nM) (Gopalakrishnan et al., 2012b).
To distinguish between FKBP51 and FKBP52 in a model
system, Gaali et al. used a chemical genetics approach to
generate artificial selectivity (Gaali et al., 2015). This approach
was originally developed to selectively target FKBP12 fusion
proteins (Clackson et al., 1998). Adapting this procedure,
Gaali et al. generated FKBP51F67V and FKBP52F67V mutants,
which featured enlarged FK506-binding sites and synthesized
complementary ligands. The desired ligand potently bound to
the mutated proteins FKBP51F67V and FKBP52F67V, facilitating
the desired study on neuronal differentiation in a cellular model.
Interestingly, during the development, the researchers noticed
that a structural analog (iFit1, Figure 6) retained some binding
affinity to WT FKBP51 but not to WT FKBP52. Analysis of the
crystal structure of the FKBP51-iFit1 complex revealed, that the
α-carbon allyl substitution stabilized a conformational change
compared to either the apo form or the FKBP51-FK506 complex
by displacing Phe67. This conformational change is hard to
achieve in FKBP52, since the resulting conformation is more
strained due to the bulky FKBP52-specific residues Thr58, Trp60,
and Val129. Synthesis of a small series with increased bulk of
the α-carbon side chain revealed a cyclohexyl ring as the most
potent residue for FKBP51 binding. The best ligands out of
this series were termed SAFit ligands for Selective Antagonist of
FKBP51 by induced fit, Figure 6). SAFit1 and SAFit2 have K i
values of 4 nM and 6 nM, respectively, and show over 10,000-fold
selectivity for FKBP51 over FKBP52. Both, SAFit1 and SAFit2,
do not show any immunosuppressive activity, since they lack the
effector domain responsible for binding to calcineurin or mTOR.
Although these are the best FKBP51 ligands published so far,
further optimizations are needed to improve the physicochemical
properties, which strongly deviate from the properties required
for CNS-directed drugs (Wager et al., 2010). In particular, SAFit1
and SAFit2 display too high molecular weights (748 and 803
g/mol, compared to 426 g/mol for 90% of CNS drugs) and too
low ligand efficiencies (LE = 0.21 and 0.19, compared to 0.37 for
90% of CNS drugs) (Gaali et al., 2016).
Based on the breakthrough with the SAFit ligands, Feng et al.
investigated the requirements for binding to the newly discovered
conformation to gain further insights into the mechanism (Feng
et al., 2015b). Since the cyclohexyl ring was found to be the
most important structural feature for selectivity, the researchers
explored the importance of the neighboring trimethoxyaryl
substituent of the SAFit ligands. They gradually removed the
methoxy substituents leading to a 30–100-fold loss in binding
affinity for FKBP51. Further reduction of the phenyl ring
revealed, that at least an additional methyl group in the α-
position seems necessary to retain selectivity for FKBP51 over
FKBP52. Subsequently, the authors applied a Crimmins-type
aldol reaction to introduce short carbon chains bearing a hydroxy
function at C10 with defined stereochemistry. Out of this series,
ligand 2 (Figure 7) displayed the best affinity toward FKBP51
(K i = 700 nM) and confirmed the FKBP51-selective induced-
fit binding mode, which seems not to be influenced by the
substitution pattern at C10. Another optimization approach by
Gaali et al. focused on the substitution of the top group part of
the SAFit ligands by using a solid-phase synthesis strategy (Gaali
et al., 2016). Replacement of the potentially labile pipecolic ester
group by a series of amides, resulted in 3 (Figure 7), containing
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FIGURE 6 | Ligands of the iFit/SAFit series.
FIGURE 7 | Derivatives of SAFit.
a geminally substituted cyclopentyl ring and displaying 20-fold
selectivity against FKBP12 (FKBP51: K i = 0.14 ± 0.02µM,
FKBP12: K i = 3.8 ± 0.006µM) and no appreciable binding to
the antagonistic FKBP52. Notably, the molecular weight of 3 was
reduced by 34% (MW = 529.7 g/mol, compared to SAFit2) and
the ligand efficiency (LE= 0.25) was improved.
Recently, Shi et al. computationally analyzed the molecular
binding mechanism and the binding trajectory of iFit4 (Figure 6)
to FKBP51 and FKBP52 (Shi et al., 2018). They used
molecular dynamics simulations, binding free energy calculations
and unbinding pathway analysis to gain insights into the
isoform selectivity. After conformational stability evaluation,
they suggested that the preference of FKBP51 and FKBP52 for
the “Phe67-in” and “Phe67-out” states are different, and therefore,
the most important factor for the selectivity. This difference is
structurally exploited by the cyclohexenyl ring in iFit4. A further
potential site for structural optimization is Gln85 in FKBP51
(Glu85 in FKBP52), as suggested previously (Bracher et al., 2013).
LeMaster et al. analyzed the structural distribution of the
residues of the FK1 domain of unliganded and iFit-bound
FKBP51 by NMR studies (LeMaster and Hernandez, 2015). As a
result, they proposed conformational selection as the mechanism
responsible for the binding to the iFit ligands, in contrast to the
induced fit mechanism proposed by Gaali et al. They suggested
that a closely related conformational transition to that of the
iFit-bound FK1 domain is also populated in the unliganded
FK1 domain. It should be noted that the binding trajectory of
SAFit ligands most likely involves conformational selection and
induced fit mechanism. The mechanistic details when and how
Phe67 is flipped out remain to be elucidated.
Pharmacological Studies With SAFit2
With the SAFit ligands in hand, it was possible to unambiguously
distinguish between FKBP51 and FKBP52. These ligands serve as
probes for FKBP51 interactions in cellular and animal models.
While SAFit1 is the ligand of choice in cellular experiments (due
to better solubility and slightly better off-target profile), SAFit2
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has much better pharmacokinetic properties and is the current
gold standard for in vivo studies (Romano et al., 2015). Using
SAFit2, Hartmann et al. were able to show reduced anxiety-
related behavior in mice (Hartmann et al., 2015).
The research group of Géranton investigated the potential
of FKBP51 as a pharmacological target for the treatment
of persistent pain. Utilizing the selective FKBP51-inhibition
through SAFit2, the research group was able to reduce
mechanical hypersensitivity seen in joint inflammatory and
neuropathic pain states in female and male mice (Maiarù
et al., 2016, 2018). Furthermore, the selective FKBP51-inhibition
also reduced the hypersensitivity in a translational model of
chemotherapy induced pain.
Balsevich et al. demonstrated that chronic treatment with
SAFit2 displayed the same metabolic effects in mice as a
FKBP51 knockout, specifically body weight reduction and
glucose tolerance improvement (Balsevich et al., 2017). The
authors identified a novel association between FKBP51 and
AS160, a substrate of AKT2, which is involved in the glucose
uptake. This interaction was reduced in samples from SAFit2-
treated mice through disruption of the AS160-FKBP51 complex.
Consequently, the authors proposed FKBP51 as a mediator
between stress and the development of type 2 diabetes.
Recent research on glioma showed, that inhibition of FKBP51
decreased the PD-L1 levels (Programmed Death Ligand 1)
in glioma cells, suggesting FKBP51 as a potential target
of immunomodulatory strategies for glioblastoma treatment
(D’Arrigo et al., 2017). Romano et al. found an interaction of
FKBP51 with the subunits of the IκB kinases (IKK) in melanoma
cells Interestingly, the IKK-FKBP51 interaction does not seem to
be dependent on the PPIase activity of FKBP51, but the kinase
activity of IKK is. The IκB kinase complex is one part of the NF-
κB signal transduction cascade and the activation of NF-κB is a
major factor of melanoma resistance to apoptosis (Romano et al.,
2015).
Different Ways of FKBP51 Inhibition
Assimon et al. showed that FKBP51 and FKBP52 have a strong
preference for binding to Hsp90 over Hsp70 (Assimon et al.,
2015). Recently, Kumar et al. illuminated the bindingmode of the
Hsp90 C-terminal peptide to the TPR domain of FKBP51 using
a combination of x-ray crystallography, differential scanning
fluorimetry and molecular dynamics simulation (Kumar et al.,
2017). They found, that the TPR domain of FKBP51 mainly
interacts with the C90 peptide via the highly conserved amino
acids Lys272, Glu273, Lys352, Asn322, and Lys329. The binding takes
place via a di-carboxylate clamp, which is a common mode of
action for TPR domain-containing proteins. Ligands targeting
the TPR domain were suggested as an alternative approach for
inhibition of FKBP51 function. However, it will require highly
negatively charged compounds that have to compete with an
intracellular protein-protein interaction (for depression in the
brain). It remains to be seen, whether the binding requirements
of the TPR domain can align with the pharmacokinetic properties
necessary for drug-like FKBP inhibition.
Another approach to target the molecular function of FKBP51
was recently described by Sabbagh et al. (2018). In a high-
throughput assay, they identified benztropine mesylate as a
ligand, which is able to attenuate the suppression of GR activity
in an FKBP51-dependant manner. Since benztropine does not
inhibit the PPIase activity of FKBP51, the underlying mode
of action is different to the aforementioned ligands like SAFit.
Further mechanistic studies are necessary to better evaluate the
potential of this promising approach.
MICROBIAL FKBPS
Antibiotics that target essential pathways in bacteria are subject
to strong natural selection, which evokes a rapid rise of resistance
(Lynch and Wiener-Kronish, 2008). Newer approaches focus
on nonessential virulence factors like bacterial secretion or
quorum sensing as targets (Baron, 2010; Sintim et al., 2010). One
important virulence factor in several gram-negative bacteria is a
close homolog to human FKBP12 called macrophage infectivity
potentiator (MIP). This was first described in Legionella
pneumophila, the causative agent for Legionnaires’ disease. It
potentiates the replication rates in human phagocytic cells and
is therefore required for intracellular infection (Cianciotto et al.,
1989). MIP and MIP-like PPIases are widely distributed in gram-
negative bacteria (Ünal and Steinert, 2014), making this family a
precious target for drug development. Structure determination
of the MIP protein from L. pneumophila by crystallization
with FK506 (Riboldi-Tunnicliffe et al., 2001) and by NMR
spectroscopy in a complex with Rapamycin (Ceymann et al.,
2008) revealed that both drugs bind via the pipecolate moiety
to the PPIase domain of MIP, indicating a strong similarity
between these complexes compared to the FKBP12 complexes
with the respective ligand. Therefore, the pipecolate functioned
as a starting point for ligand development. Juli et al. built
upon work of Holt et al. (1993, 1994) and synthesized novel
derivatives of this scaffold. Although one compound displayed
high activity against the FKBP domain of Legionella MIP (IC50
= 6µM), no influence on the replication of L. pneumophila
in human cells was observed (Juli et al., 2011). Subsequent
improved analogs, however, inhibited replication of Chlamydia
trachomatis and reduced intracellular survival ofNeisseria species
(Reimer et al., 2016; Seufert et al., 2016). Recently, Pomplun
et al. developed bicyclic ligands with high affinities for microbial
FKBPs and MIPs (Ligands 4, 5, and 6, Figure 8), including
Plasmodium falciparum, Legionella pneumophila as well as
Chlamydia pneumoniae and trachomatis.
The best ligands were able to inhibit proliferation of
L. pneumophila and reduce infectivity of aforementioned
Chlamydias. and decrease parasitemia in P. falciparum. However,
the mode of action still needs to be elucidated. The authors
suggested a key role of the PPIase domain and raised the
question of participation of human FKBPs (Pomplun et al.,
2018). Rasch et al. synthesized novel non-pipecolate ligands
by combining two previously described FKBP-binding motifs,
namely cycloheximide (Christner et al., 1999) and adamantane
(Babine et al., 1995; Norville et al., 2011). These derivatives
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FIGURE 8 | Ligands for the pathogens Plasmodium falciparum, Legionella pneumophila, Chlamydia pneumoniae, and C. trachomatis.
displayed lower IC50 values and improved selectivity for MIP
(although FKBP12 was still 10-fold better inhibited) and
inhibited bacterial growth in liquid culture. Notably, the effect
was independent of MIP, since the same effect was shown in
1mip-mutants (Rasch et al., 2015).
Recently, interest arose in L-685,818 (a competitive
antagonist of FK506), which binds to FKBP12 but displays
no immunosuppressive effects and does not inhibit calcineurin
(Dumont et al., 1992; Organ et al., 1993). Nambu et al. were
interested in the development of new treatments for systemic
fungal infections, especially the two important pathogenic fungi,
Cryptococcus neoformans and Aspergillus fumigatus. The growth
of these fungi is dependent on calcineurin and can therefore be
inhibited by FK506, as was shown before (Odom et al., 1997a,b;
Cruz et al., 2000; Steinbach et al., 2006, 2007; Lev et al., 2012).
Since FK506 also exhibits effects e.g. immunosuppressive activity
and calcineurin inhibition in mammalian cells, it is essential to
prevent these cells from interactions by blocking the binding
site of FKBP12. Therefore, Nambu et al. developed antagonists
for FK506, which were designed to preferentially permeate
mammalian cells, but not fungal pathogens. The best compounds
of this study bound as tightly to FKBP12 as FK506 and were able
to inhibit A. fumigatus proliferation up to 24% (compared to
untreated controls), when co-administered with FK506 (Nambu
et al., 2017). Further improvements regarding the selectivity of
permeation as well as studies in mice are needed before this
concept can be used in antifungal therapy.
CHEMICAL TOOLS/CHEMICALLY
INDUCED DIMERIZATION UTILIZING
FKBPS
The general idea for chemical dimerization with FKBP ligands
is based on constructing fusion proteins consisting of a
dimerization-domain and proteins of interest (POI). The aim is
to induce the interaction of these proteins by addition of a small
molecule. Afterwards, the follow-up cellular responses can be
observed (Figure 9).
Several of the natural immunophilin ligands were found to
be useful as chemical tools in the field of chemically induced
FIGURE 9 | The CID system (here shown for homo-dimerization). Fusion
proteins of the proteins of interest tagged with the respective dimerization
domains. The controlled interaction starts upon administration of the dimerizer
ligand.
dimerization (CID). For CIDs utilizing FKBPs, a fusion protein
of the POIs and the immunophilin is necessary. An example for
a natural asymmetric dimerizer is Rapamycin and its analogs
(rapalogs), which bind FKBP12 and the FRB domain of mTOR1
(mammalian target of Rapamycin complex 1). Another example
is FK506, which binds FKBP12 and calcineurin. Symmetrical
dimerization can be induced by treatment with a bivalent ligand
like synthetic dimers of FK506 or Rapamycin. This dimerization
process is mostly used to observe cellular processes, some of
which are the localization of signal proteins, the activation of
receptors and the regulation of DNA transcription. As there are
already several reviews on CIDs (Kley, 2004; Gaali et al., 2011;
Stanton et al., 2018), this review will only give a short overview
of earlier publications and focus on developments over the last
years.
Natural Immunophilin Ligands
The natural immunophilin ligands FK506 and Rapamycin
are well established as CIDs with Rapamycin as the most
prominent agent, possibly due to the easy handling of the
FRB domain (Rivera et al., 1996; Ye et al., 1999; Kohler and
Bertozzi, 2003; Komatsu et al., 2010; Robinson et al., 2010). The
immunosuppressive properties of Rapamycin and the unspecific
binding of endogenous FRB and FKBP12 can confound the
actually intended results. Thus, many non-immunosuppressive
Rapamycin derivatives and engineered cognate protein mutants
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FIGURE 10 | Structures of rapalogs.
were created using the “bump-and-hole” approach. These
derivatives abolished binding to the wild type FRB and
selectively bound to a FRB triple mutant (T2098L, W2101F,
and K2095P) instead (Liberles et al., 1997; Stankunas et al.,
2003). Further developments on the FRB binding loop improved
the pharmacokinetic parameters of the rapalogs for instance
AP21967 (Pollock et al., 2002) and iRap (Figure 10) (Inoue
et al., 2005). Additionally, photoinducible variants were designed
including cRap (Umeda et al., 2011) and pRap (Karginov et al.,
2011).
FK506 was derivatized resulting in a bumped version (C40-
p-phenoxyphenyl-FK506) and a cognate calcineurin mutant
(Clemons et al., 2002). Additionally, a symmetric bivalent
dimerizer of FK506 (FK1012) was synthesized, which abolished
binding to calcineurin (Spencer et al., 1993). Recently, Guo et al.
simplified the synthesis of this dimerizer by a one-step thiol-ene
reaction (Guo et al., 2014).
Fully Synthetic Bivalent Dimerizers
Fully synthetic but unselective FKBP ligands were developed
by Holt et al. (1993). Further derivatization at the propyl
bridged biphenyl moiety yielded an improved ligand
regarding the affinity toward FKBP12. This monomeric
ligand is mostly known as SLF (Figure 5). The bivalent
version synthesized by Ariad Pharmaceuticals was named
AP1510 (Figure 11) (Amara et al., 1997; Keenan et al.,
1998).
The undesirable binding of endogenous FKBPs was abolished
by a “bump-and-hole” approach. Clackson et al. developed the
selective bivalent ligand AP1903 for the FKBP12F36V mutant
(Figure 11) (Clackson et al., 1998). Regarding the nature of
the linker for the symmetric CIDs a variety of derivatives were
synthesized, but the most utilized one is AP20187 (Figure 12),
which is nowadays sold by TaKaRa Bio. The superiority of
this ligand is based on its increased solubility in aqueous
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FIGURE 11 | Structures of the bivalent ligands AP1510 and AP1903.
solution. Yang et al. further developed monomeric forms (Yang
et al., 2000), which were improved by Banaszynski et al.
and named SLF∗ and Shld1 (Figure 12) (Banaszynski et al.,
2006).
Interestingly, the Shld1 synthesis was recently optimized by
Jorgensen and Bols (2018).
Usage of FKBP Ligand CIDs as Chemical
Tools
CIDs are used in hetero/homodimerization and oligomerization,
especially for the activation of receptors, some of which
are the TGF-β receptor (Stockwell and Schreiber, 1998),
epithelial growth factor receptor, hepatocyte growth factor and
thrombopoietin receptor (Li et al., 2002), membrane tyrosine
kinases (Spencer et al., 1993), insulin receptor (platelet-derived
growth factor β) (Yang et al., 1998) and chimeric insulin receptor
LFv2IRE (Cotugno et al., 2004). Furthermore, CIDs can be
used to induce activation of apoptosis (Belshaw et al., 1996;
Amara et al., 1997; Tsuruma et al., 2004; Landskroner-Eiger
et al., 2010). For instance, an inducible mutant of caspase-
9, iCasp9, which binds AP20187 was engineered to initiate
apoptosis in vivo. Mice, transfected with colorectal cancer stem
cells containing iCasp9 in their genome, were found to have
strongly decreased tumor sizes after treatment with AP20187
(Kemper et al., 2012). The directed and controlled cell death
is also used as a suicide switch in the study of transfected and
modified T cells in vivo. Accordingly, caspase-8 was hybridized
to be able to activate apoptosis utilizing AP20187 and therefore
preventing unwanted proliferation (Khaleghi et al., 2012). T cells
used in tumor therapy were modified to use iCasp9 and AP1903
(Clackson et al., 1998; Iuliucci et al., 2001) in the same manner
by Zhou and Brenner (2016). RapaCas9, a caspase-9 dimerizable
by Rapamycin treatment, was constructed recently to utilize the
readily available drug (Stavrou et al., 2018).
In 2014 Ahmed et al. introduced a photocleavable variant
of AP20187 (PhAP) (Figure 13), which enables reversible
dimerization. This was tested in cells by an endosome dispersion
assay employing the fusion protein EGFP-FKBP-LC8TRAP.
EGFP (enhanced green fluorescent protein) was fused to the
FKBP12F36V mutant and LC8TRAP. LC8TRAP is a dynein light
chain (LC8) low affinity binding peptide, which binds tightly to
LC8 after dimerization. Interference with the dynein promoted
processes leads to a visible change in endosome dispersion. PhAP
was found to behave in a similar manner as AP20187, although
it is possible to reverse the induced effect by the dimerizer
with an additional handle (Ahmed et al., 2014). Proteins and
Frontiers in Pharmacology | www.frontiersin.org 13 December 2018 | Volume 9 | Article 1425
Kolos et al. FKBP Ligands
FIGURE 12 | Structures of the selective bivalent dimerizer AP20187 and its monomeric precursors.
receptor complexes, which not only need dimerization but
oligomerization for activation, could be introduced by a system
developed by Inobe et al. By adjusting the configuration and
linker regions of fusion proteins of FRB and FKBP12, they were
able to reach controlled Rapamycin inducible tetramer formation
which was verified by tetramerizing aminopeptidase N and p53
(Inobe and Nukina, 2016). Recently, Chen et al. researched
on the insulin receptor pathway and were able to differentiate
between the insulin receptor types of the insulin-like growth
factor receptor 1 (IGF1R) and the insulin receptor (InsR) as
well as the respective hybrid of the heterodimer of both (HybR).
The bivalent homodimerizer AP20187 and the heterodimerizer
AP21967 were used as CIDs (Chen et al., 2018).
Another field where CIDs are applied is the regulation
of transcription. Analogously to the yeast-two-hybrid (Y2H)
assay, Rivera and Ho used CIDs to affect DNA transcription
utilizing the gal-4 and zinc finger homeodomain 1 (ZFHD1)
promoter regions (Ho et al., 1996; Rivera et al., 1996). A
similarly developed method, the yeast-three-hybrid assay (Y3H),
is mostly used to scan for small molecule protein targets or
in a screening for specific protein mutations (Licitra and Liu,
1996; Althoff and Cornish, 2002; Kley, 2004). New methods
for bacterial genome control were introduced by Becker et al.
They designed homodimeric DNA looping proteins (TALEs),
which are able to repress DNA transcription at a certain
point by adding the dimerizer AP20187 (Becker et al., 2018).
This system is comparable to the yeast-two-hybrid system for
chemical transcription regulation. More recently, researchers
focused on DNA modifications and epigenetics. Konishi et al.
showed, that the telomeric repeat binding factor 2 (TRF2) binds
to core histones to protect chromosome ends from DNA damage
response and thus loss of telomeric DNA. This was achieved
by dimerizing fusion proteins of a core histone with TRF2
with the rapalog AP21967 (Konishi et al., 2016). Furthermore,
DNA methylation and its further impact were investigated by
engineering a ten-eleven translocation protein (TET). TET2,
which catalyzes the transformation of 5-methylcytosine (5mC)
to 5-hydroxymethyl cytosine (5hmC) on DNA strands, plays
a role in the first steps of DNA demethylation. TET2 was
genetically split and each part fused to FKBP12 to control
epigenetic remodeling by addition of CIDs (Lee et al., 2017).
To further understand the link between epigenetic markers
and gene expression, a CID-inducible FIRE-Cas9 system was
established. Here, a Cas9 and a chromatin regulating enzyme
complex [Hp1/Suv39h1 or mSWI/SNF (BAF)] can be dimerized
with histones using Rapamycin. This showed that recruitment
of these complexes modifies nearby histone marks (Braun et al.,
2017).
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FIGURE 13 | Structure of the chemical epigenetic modifier consisting of a FK506 and HDAC-Inhibitor moiety and the structure of the photocleavable selective bivalent
dimerizer PhAP.
Another recently published tool for the repression of DNA
transcription utilizes histones. As a certain histone acetylation
state is repressing transcription, Butler et al. developed a
chemical epigenetic modifier (CEM, Figure 13) consisting of
FK506 and a HDAC enzyme inhibitor which amplifies the
restrictive acetylation state. Similar to the Y2H assay, Gal4
and FKBP12 were fused together to be able to recruit HDAC
upon CEM administration to a specified gene region with Gal4
as promoter. HDAC itself consists of a huge protein complex
and inhibition of one site does not inhibit its activity. The
HDAC complexes affected local histone marks as reporter gene
expression decreased by nearly 50% (Butler et al., 2018). In
addition to the CRISPR/Cas9 system for genome editing a split
Cas9 architecture for inducible genome editing was created. This
inducible Cas9 might enable tissue specific activation of gene
transcription with orthogonal dimerizer strategies in the future
(Zetsche et al., 2015).
Another major research area where CIDs are useful is the
elucidation of the mechanisms of protein functions and the
transport and localization of proteins and vesicles. The latter
can be achieved by fixating signaling proteins on to the cellular
membrane and switching on cellular processes. This was done
with the guanine nucleotide exchange factor son of sevenless
(SOS) (Holsinger et al., 1995). Furthermore, nuclear trafficking
control (Xu et al., 2010) and transport proteins like dynein,
kinesins and myosins were investigated (Kapitein et al., 2010). To
study lipid signaling of phosphatidylinositol 3,4,5-trisphosphate
(PIP3) release, a reversible dimerizer consisting of a SNAP-
tag site and the Shld ligand was synthesized. This reversible
chemical dimerizer (rCD1) (Figure 14) has a SNAP-tag for
permanent binding, but the Shld ligand can be competitively
eluted with FK506 or the non-immunosuppressive rapalog
AP23102.
To observe lipid signaling a Lck-ECFP-SNAP fusion protein
was constructed. The Lck protein localizes the construct on
the plasma membrane. The enhanced cyan fluorescent protein
(ECFP) is used for the visualization and SNAP for the permanent
binding of the SNAP-tag on the dimerizer. By recruiting
an iSH2-mRFP-FKBP12 fusion protein to the cell membrane
phosphatidylinositol 3-kinase (PI3K) is activated and PIP3
released. The inter-Src homology 2 domain (iSH2) is activating
PI3K, red fluorescent protein (mRFP) is added for visualization
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FIGURE 14 | The structure of the reversible chemical dimerizer rCD1, the
structures of the PROTACs dTAG13 (ortho Shld1 regioisomer) and dTAG51
and the structures of AP22542 and AP21998 which are used in reverse
dimerization to dissolve the FKBP12 dimer.
and the FKBP12 mutant for Shld binding. PIP3 level is observed
by a second messenger, the pleckstrin homology domain of
Akt (PH) fused to green fluorescent protein (EGFP) (Feng
et al., 2014). Additionally, PIP2 conversion to PI (4)P was made
observable by Schifferer et al. by using Lck-ECFP-SNAP with a
mRFP-FKBP-5Ptase and EGFP-PLCδ-PH fusion protein. PLCδ-
PH is binding to PIP2 on the membrane and the 5Ptase is
transforming PIP2 to PI (4)P. Thus, PIP2 levels on themembrane
can be visualized by monitoring the release of EGFP-PLCδ-PH
from the membrane (Schifferer et al., 2015).
There is always a high demand for tools to mimic or insert
posttranslational modifications (PTMs). With the CID systems
it is possible to address several PTMs, for instance, sumoylation
(Zhu et al., 2006; Zimnik et al., 2009) and protein autoregulation
like intein splicing (Mootz et al., 2003). Karginov et al. were
able to allosterically activate kinases with CIDs to regulate
phosphorylation levels. The fusion protein FAK-iFKBP did only
show kinase activity by binding of Rapamycin together with the
FRB protein. FAK is the focal adhesion kinase, whereas iFKBP
is a truncated version of FKBP12 inserted into the kinase. The
iFKBP insertion renders the kinase inactive. However, binding
of Rapamycin restored kinase activity. Successful regulation at
the same conserved site of the kinases Src and p38 shows the
transferability of this system (Karginov et al., 2010). Additionally,
kinase activation by the photoinducible Rapamycin derivative
pRapwas successfully tested (Karginov et al., 2011). Furthermore,
another system for kinase control was established by Dagliyan
et al. Fusion of a UniRapR-domain to a Src kinase exhibited
regulatory activity by acting as a conformational switch. This
UniRapR-domain simply consists of a FKBP12 and FRB fusion.
While insertion of the UniRapR-domain at a specific site
depleted Src activity completely, binding of Rapamycin or iRap
fully restored the kinase activity. Comparing the effect of the
Rapamycin activation of the Src-UniRapR fusion protein and
an inactive Src mutant in single cells showed that the cells with
the activated kinase started to spread and increase their cell
area. Further studies of Src-UniRap activation in epidermal cells
of zebrafish embryos showed a morphological change of the
cell shapes resulting in less cell-cell contacts. This confirms the
already known role of Src in tumor metastasis (Dagliyan et al.,
2013).
Camacho-Soto et al. pursued another approach of CID
directed kinase activation by creating ligand gated split kinases.
They successfully split several kinases (Lyn, Fak, Src, and PKA)
and fused their split domains with FKBP12 and FRB respectively.
Addition of Rapamycin reconstitutes the enzyme and its activity
(Camacho-Soto et al., 2014a). Further development also enabled
split-phosphatases and moreover an orthogonal system of
split-phosphatase and kinase (Camacho-Soto et al., 2014b). Here
the orthogonality was obtained by using additional CIDs which
utilize other ligand-receptor systems (abscisic acid).
A new area emerging in CID research are small-molecule
protein degraders, the proteolysis targeting chimeras
(PROTACs). Directed protein degradation with a built in
on-switch can be a useful tool to discern a sudden knockout
of a specified protein and the biological responses. PROTACs
might be even used as new type of drug modality (Churcher,
2018). A PROTAC in general consists of a ligand binding to
a ubiquitin ligase (E3) which is connected to a ligand binding
the protein target. Polyubiquitination of proteins is known to
be a marker for protein lifetime. By bringing the target protein
in the proximity of the E3 ligase, its ubiquitination will be
prolonged until the protein is recognized by the proteasome
complex and degraded. The Crews group, which first reported
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the application of PROTACs, recently constructed FKBP12F36V
binding PROTACs to find new E3 ubiquitin ligases as PROTAC
targets. To be able to assess the functionality of the PROTACs,
a EGFP-FKBP12F36V reporter system was applied. The EGFP
degradation was a direct observable parameter for a positive
outcome. Utilizing this fusion system theoretically renders
any protein amenable to PROTAC induced degradation (Ottis
et al., 2017). Recently, Nabet et al. constructed FKBP12F36V
degrading PROTACs containing the ligand dTAG51 or the
ortho regioisomer dTAG13 (Figure 14), coupled to the cereblon
E3-ligase ligand thalidomide.
Interestingly, the ortho regioisomer bound more selectively
to the FKBP12 mutant than the original meta one. The dTAG
system was made generalizable to study divergent proteins by
introducing the CRISPR/Cas9 system to reach locus-specific
insertion of FKBP12F36V. Treatment of cells with the fusion
proteins by the selective dTAGs lead to rapid reduction in POI
concentration. This was tested successfully for the bromodomain
isoform BR4 and the oncoprotein KRASG12V in cells. The
degradation of a luciferase coupled FKBP (luc-FKBP12F36V)
was also tested in vivo. Mice were engrafted in their bone
marrow with the human leukemia cell line MV4;11 carrying
the luc-FKBP12F36V vehicle. By administering the drug (dTAG)
they were able to monitor a rapid and durable decrease in
bioluminescense, which was reversible after withdrawal of the
drug (Nabet et al., 2018). This is a promising start for future
drug development built on PROTACs and a universal usable
tool for protein degradation, although it has to be kept in
mind, that the creation of fusion proteins always requires the
test of functionality of the fusion protein. Furthermore, for the
development of PROTAC-drugs a directly POI binding ligand
has to be synthesized.
Immunophilin Ligands Used in Reverse
Dimerization
Interestingly, mutants for FKBP12 were also designed to reach
dimerization without ligand treatment. These FKBP12F36M
mutants were created by Rollins et al. and could be disrupted by
the addition of monomeric Shld1 derivatives like AP22542 and
AP21998 (Rollins et al., 2000). With this reverse dimerization
system Rivera et al. were able to regulate protein secretion
through controlled protein aggregation in the ER. POIs were
fused together with four equivalents of the FKBP12F36M mutant
and a signal sequence for ER transport. Additionally, a furin
cleavage site was inserted between the FKBPs and the POI.
The proteins carrying the signal sequence were assembled in
the ER and started to build complexes, which were too big
for vesicle transport. After ligand administration (AP22542 or
AP21998, Figure 14) the constructs dissolved, and the POI
hybrid was released. Finally, cleavage by furin unveiled its
native form preventing a reaction of the immune system. This
approach was already used to secret therapeutic proteins like
proinsulin or the growth hormone (GH) in cells. The release of
proinsulin was also tested in vivo with diabetic mouse models
showing promising results (Rivera et al., 2000). Al-Bassam
et al. used the same system to monitor movements of post-
Golgi transport vesicles in neurons. Neuronal transmembrane
proteins are known to be transported in vesicles, that traffic
solely within the somatodendritic compartment to the dendrites.
They created a pulse-chase system, which allows the spontaneous
release of fluorescently labeled transmembrane proteins to follow
the vesicles transport (Al-Bassam et al., 2012). Recently, the
FKBP12F36M mutant was improved by Barrero et al. who
introduced a F36L mutation instead. This mutant dimerizes
readily and has additionally better ligand binding capabilities
and might lead to further utilization of this dimerizing system
(Barrero et al., 2016). Tonthat et al. found a formation of dimers
in the apo crystal structures of fungal FKBP12 (A. fumigatus,
C. albicans, and C. glabrata). These dimers revealed the binding
of a proline residue (located in the 80s loop of FKBP12) to the
active site of another FKBP12 protein unit. A mono cysteine
mutant (V91C) of A. fumigatus FKBP12 formed the dimer in
solution by disulfide bridging. This might elucidate the substrate
specifics of the PPIase site in FKBP12. Additionally, this putative
FKBP12 self-catalysis might be a self-regulatory action of the
protein (Tonthat et al., 2016).
CONCLUSION
FKBP research has historically focused on human FKBP12,
but more recently several other homologs have received
increasing attention (e.g., FKBP12.6, FKBP51, AIPL1). Human
FKBPs discussed in this review have been summarized in
Table 1, to get a comprehensive idea of the key aspects of these
proteins. Note that there are many more human FKBPs
which are not mentioned due to poor characterization
and/or understanding of their biophysical properties.
Additionally, the effects of ligands on the respective proteins
have been omitted since many effects are controversially
discussed.
Several themes that are noteworthy:
(1) Besides the name, many FKBPs do not bind FK506 or do
so poorly. They are better described as FKBP-like proteins.
So far, the FK506-binding potential is closely correlated with
sequence homology to the active site of FKBP12.
(2) For pharmacological studies of FKBPs, FK506 or Rapamycin
are suboptimal tools since they also block calcineurin or
mTOR as confounding factors. Well characterized, highly
potent, non-immunosupressive analogs are available such as
FK1706 or bicyclic analogs. GPI1406 is an extremely poor
FKBP ligand.
(3) Many FKBPs do not have a measurable PPIase activity,
although some can or might be activated by biochemical
stimuli. For weak PPIase activity care has to be taken of
avoiding contaminations with high PPIase activity (e.g., E.
coli SlyD). Binding of ligands to FKBPs should always be
confirmed by biophysical assays (fluorescence polarization,
isothermal calorimetry, NMR), which are available for many
FKBPs.
(4) Even for FKBPs with a clearly established PPIase activity,
the physiological role of this activity remains to be
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established. The biochemical functions documented so far
invoke protein-protein interactions (e.g., FKBP12/12.6-RyR,
FKBP12-TGFβR1, AIPL1-Farnesyl-PDE6).
(5) The FK506-binding pocket of FKBPs can be plastic and this
can be important for their function (AIPL1, FKBP51). It also
offers new opportunities for the development of selective
FKBP ligands.
(6) Several FKBPs have intertwined functions with overlapping
substrates (FKBP12/12.6-RyR1/2, FKBP51/52-GR/AR).
It is essential, to perform control experiments and
check for compensatory effects in genetic studies.
Additionally, more selective pharmacological tools are
required.
Finally, it should be kept in mind that there are still many
(human) FKBPs that we hardly know anything about.
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